MCID: DYS009
MIFTS: 51

Dysthymic Disorder

Categories: Mental diseases

Aliases & Classifications for Dysthymic Disorder

MalaCards integrated aliases for Dysthymic Disorder:

Name: Dysthymic Disorder 12 44 15 17 70
Dysthymia 12 73 54 15 32

Classifications:



External Ids:

Disease Ontology 12 DOID:12139
ICD9CM 34 300.4
MeSH 44 D019263
NCIt 50 C34562
SNOMED-CT 67 192384008
ICD10 32 F34.1
UMLS 70 C0013415

Summaries for Dysthymic Disorder

Disease Ontology : 12 A mood disorder that involves the presence of a low mood almost daily over a span of at least two years.

MalaCards based summary : Dysthymic Disorder, also known as dysthymia, is related to depression and obsessive-compulsive personality disorder. An important gene associated with Dysthymic Disorder is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Circadian rythm related genes and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Testosterone and Methyltestosterone have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and spinal cord, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 73 Dysthymia, also known as persistent depressive disorder (PDD), is a mood disorder consisting of the same... more...

Related Diseases for Dysthymic Disorder

Diseases related to Dysthymic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 279)
# Related Disease Score Top Affiliating Genes
1 depression 30.6 SLC6A4 MAOA HTR2C HTR2A HTR1A CRH
2 obsessive-compulsive personality disorder 30.3 SLC6A4 HTR2A COMT
3 schizotypal personality disorder 30.1 PRODH HTR2A COMT
4 migraine without aura 30.0 SLC6A4 HTR1A DRD4
5 cyclothymic disorder 30.0 SLC6A4 HTR2C HTR2A DRD4 COMT
6 diabetes insipidus 29.9 POMC INS CRH
7 migraine with aura 29.9 SLC6A4 SLC6A3 HTR2C HTR2A
8 autonomic nervous system disease 29.7 INS IL6 DRD4
9 separation anxiety disorder 29.7 SLC6A4 SLC6A3 MAOA HTR1A DRD4 CTU2
10 social phobia 29.7 SLC6A4 PRODH MAOA HTR2A HTR1A CTU2
11 hypochondriasis 29.6 SLC6A4 POMC HTR2C HTR2A HTR1A BDNF
12 somatization disorder 29.6 SLC6A4 POMC IL6 HTR1A CRH COMT
13 conduct disorder 29.6 SLC6A4 SLC6A3 POMC MAOA DRD4 COMT
14 cannabis abuse 29.5 PRODH HTR1A DRD4 COMT BDNF
15 personality disorder 29.4 SLC6A4 SLC6A3 MAOA HTR2C HTR2A HTR1A
16 neurotic disorder 29.4 SLC6A4 POMC MAOA INS IL6 HTR2A
17 bipolar i disorder 29.4 SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
18 adjustment disorder 29.4 SLC6A4 POMC HTR2A HTR1A HCRT CRH
19 generalized anxiety disorder 29.3 SLC6A4 SLC6A3 SLC6A2 MAOA HTR2A HTR1A
20 vascular dementia 29.3 IL6 HTR1A CRP
21 antisocial personality disorder 29.3 SLC6A4 SLC6A3 MAOA HTR2A DRD4 COMT
22 alcohol use disorder 29.3 SLC6A4 SLC6A3 PRODH HTR2C HTR2A HTR1A
23 acute stress disorder 29.2 SLC6A4 POMC IL6 HTR1A CRP CRH
24 melancholia 29.2 SLC6A4 POMC MAOA IL6 HTR2A HTR1A
25 post-traumatic stress disorder 29.1 SLC6A4 POMC MAOA HTR2A CRP CRH
26 oppositional defiant disorder 28.9 SLC6A4 SLC6A3 SLC6A2 MAOA HTR2A DRD4
27 borderline personality disorder 28.9 SLC6A4 SLC6A3 MAOA HTR2C HTR2A HTR1A
28 atypical depressive disorder 28.9 SLC6A4 POMC MAOA IL6 HTR2A HTR1A
29 eating disorder 28.9 SLC6A4 SLC6A3 POMC HTR2C HTR2A HCRT
30 constipation 28.8 SLC6A4 SLC6A2 INS IL6 CRP BDNF
31 phobia, specific 28.8 SLC6A4 PRODH POLI MAOA HTR2A HTR1A
32 bulimia nervosa 28.7 SLC6A4 MAOA INS HTR2C HTR2A DRD4
33 irritable bowel syndrome 28.6 SLC6A4 POMC IL6 HTR2A HTR1A CRP
34 chronic fatigue syndrome 28.6 SLC6A4 POMC MAOA INS IL6 HTR2A
35 endogenous depression 28.5 SLC6A4 SLC6A3 POMC MAOA INS IL6
36 psychotic disorder 28.3 SLC6A4 SLC6A3 PRODH MAOA HTR2C HTR2A
37 obsessive-compulsive disorder 28.3 SLC6A4 SLC6A3 POMC MAOA IL6 HTR2C
38 attention deficit-hyperactivity disorder 28.3 SLC6A4 SLC6A3 SLC6A2 PRODH MAOA IL6
39 panic disorder 28.2 SLC6A4 SLC6A3 SLC6A2 POMC MAOA HTR2C
40 mood disorder 28.1 SLC6A4 SLC6A3 SLC6A2 PRODH POMC MAOA
41 mental depression 27.8 SLC6A4 SLC6A3 SLC6A2 PRODH POMC MAOA
42 alcohol dependence 27.8 SLC6A4 SLC6A3 SLC6A2 POMC MAOA HTR2C
43 major depressive disorder 27.8 SLC6A4 SLC6A3 SLC6A2 POMC MAOA IL6
44 substance abuse 27.5 SLC6A4 SLC6A3 PRODH POMC MAOA INS
45 anorexia nervosa 27.4 SLC6A4 SLC6A2 POMC MAOA INS HTR2C
46 bipolar disorder 27.2 SLC6A4 SLC6A3 SLC6A2 PRODH MAOA IL6
47 anxiety 27.1 SLC6A4 SLC6A3 SLC6A2 PRODH POMC MAOA
48 migraine with or without aura 1 27.1 SLC6A4 SLC6A3 POMC MAOA INS IL6
49 sleep disorder 27.0 SLC6A4 SLC6A3 PRODH POMC INS IL6
50 schizophrenia 26.2 SLC6A4 SLC6A3 SLC6A2 PRODH POMC MAOA

Comorbidity relations with Dysthymic Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 52)


Active Peptic Ulcer Disease Acute Cystitis
Adjustment Disorder Anxiety
Atrophic Gastritis Atypical Depressive Disorder
Avoidant Personality Disorder Benign Essential Hypertension
Borderline Personality Disorder Bronchitis
Chronic Pulmonary Heart Disease Conversion Disorder
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dyskinesia of Esophagus
Esophagitis Familial Atrial Fibrillation
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Histrionic Personality Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Irritable Bowel Syndrome
Major Depressive Disorder Mitral Valve Disease
Mood Disorder Narcissistic Personality Disorder
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Opioid Addiction Oral Candidiasis
Osteoarthritis Osteoporosis
Paralytic Ileus Parkinson Disease, Late-Onset
Peripheral Vascular Disease Personality Disorder
Postinflammatory Pulmonary Fibrosis Post-Traumatic Stress Disorder
Postural Orthostatic Tachycardia Syndrome Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Social Phobia Somatization Disorder

Graphical network of the top 20 diseases related to Dysthymic Disorder:



Diseases related to Dysthymic Disorder

Symptoms & Phenotypes for Dysthymic Disorder

MGI Mouse Phenotypes related to Dysthymic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 BDNF COMT CRH CRY2 DRD4 HCRT
2 homeostasis/metabolism MP:0005376 10.21 BDNF COMT CRH CRP CRY2 DRD4
3 cardiovascular system MP:0005385 10.06 COMT CRP CRY2 HCRT HTR1A IL6
4 integument MP:0010771 9.9 BDNF CRH CRY2 HTR2C IL6 INS
5 muscle MP:0005369 9.56 CRY2 HCRT HTR2A HTR2C IL6 INS
6 nervous system MP:0003631 9.53 BDNF COMT CRH CRY2 DRD4 HCRT

Drugs & Therapeutics for Dysthymic Disorder

Drugs for Dysthymic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone Approved, Investigational Phase 4 58-22-0 6013
2
Methyltestosterone Approved Phase 4 58-18-4 6010
3
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
4
Testosterone enanthate Approved Phase 4 315-37-7 9416
5
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
6
Imipramine Approved Phase 4 50-49-7 3696
7 Anabolic Agents Phase 4
8 Hormone Antagonists Phase 4
9 Hormones Phase 4
10 Antineoplastic Agents, Hormonal Phase 4
11 Testosterone 17 beta-cypionate Phase 4
12 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
13 Analgesics Phase 4
14 Monoamine Oxidase Inhibitors Phase 4
15 Parasympatholytics Phase 4
16 Cholinergic Agents Phase 4
17 Muscarinic Antagonists Phase 4
18 Cholinergic Antagonists Phase 4
19 Antiparkinson Agents Phase 4
20 Central Nervous System Stimulants Phase 4
21 Antidepressive Agents, Tricyclic Phase 4
22
Norepinephrine Approved Phase 2 51-41-2 439260
23
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
24
Citalopram Approved Phase 2 59729-33-8 2771
25
Sertraline Approved Phase 2 79617-96-2 68617
26
Mirtazapine Approved Phase 2 85650-52-8, 61337-67-5 4205
27
Paroxetine Approved, Investigational Phase 2 61869-08-7 43815
28
Dexetimide Withdrawn Phase 2 21888-98-2
29 Venlafaxine Hydrochloride Phase 2
30 Desvenlafaxine Succinate Phase 2 386750-22-7
31 Duloxetine Hydrochloride Phase 2
32 Adrenergic alpha-Agonists Phase 2
33 Vasoconstrictor Agents Phase 2
34 Sympathomimetics Phase 2
35 Adrenergic Agents Phase 2
36 Adrenergic Agonists Phase 2
37 Cardiotonic Agents Phase 2
38 Protective Agents Phase 2
39
Lithium carbonate Approved 554-13-2
40
Levonorgestrel Approved, Investigational 797-63-7, 17489-40-6 13109
41
Medroxyprogesterone acetate Approved, Investigational 71-58-9
42
Ethanol Approved 64-17-5 702
43 Contraceptive Agents
44 Contraceptives, Oral
45 Contraceptives, Oral, Combined
46
Medroxyprogesterone 520-85-4 10631
47 Quetiapine Fumarate 111974-72-2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Testosterone Replacement in Treating Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
2 Duloxetine for Chronic Depression: a Double-blind Study Completed NCT00360724 Phase 4 Duloxetine (Cymbalta)
3 A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study Completed NCT00592384 Phase 4 venlafaxine XR;placebo
4 An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder Completed NCT01852383 Phase 4 Duloxetine
5 Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder Completed NCT00220701 Phase 4 Lexapro (escitalopram)
6 Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL Completed NCT00225251 Phase 4 bupropion XL
7 Escitalopram vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression Completed NCT00234312 Phase 4 escitalopram and sertraline
8 Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder Completed NCT00518986 Phase 4 armodafinil;placebo
9 Desvenlafaxine (Pristiq) vs. Placebo in the Treatment of Chronic Depression Completed NCT01537068 Phase 4 Desvenlafaxine;Placebo
10 Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment Completed NCT00296777 Phase 4 Escitalopram;Bupropion;Imipramine
11 Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication. Completed NCT00296712 Phase 4 escitalopram + bupropion
12 Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults Completed NCT01973283 Phase 4 Antidepressant Medication
13 A Comparison of Medication Augmentation and Problem Solving Therapy Withdrawn NCT01942187 Phase 4 Aripiprazole;Bupropion
14 A Stepped Care Model of Adolescent Depression Treatment in Primary Care Completed NCT01443715 Phase 2, Phase 3
15 An Open Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior Completed NCT01447602 Phase 3
16 Dichotic Listening as a Predictor of Placebo and Medication Response in Depression Completed NCT00296725 Phase 1, Phase 2 Fluoxetine;Imipramine
17 Engagement and Alliance in CBT for Depressed Adolescents Completed NCT00073359 Phase 1, Phase 2
18 The Efficacy of Parent Involvement in the Treatment of Adolescent Depression Completed NCT00883519 Phase 1, Phase 2
19 eIMPACT-DM Pilot Trial: Depression Treatment to Reduce the Excess Diabetes Risk of People With Depression and Prediabetes Recruiting NCT04437485 Phase 2 Antidepressant Medications
20 eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Active, not recruiting NCT02458690 Phase 2 Antidepressant Medications
21 An Open Clinical Trial of Interpersonal Psychotherapy for Depressed Adolescence and Parents Completed NCT00619411 Phase 1
22 Can E-therapies Reduce Waiting Lists in Secondary Mental Health Care? A Randomized Controlled Trial Unknown status NCT02423733
23 Internet-delivered Transdiagnostic Intervention for Anxiety and Depression in Romania- A Randomized Control Trial Unknown status NCT02739607
24 RECOVERY: An Internet-delivered Transdiagnostic Cognitive Behavior Therapy in Romania Unknown status NCT03917550
25 Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression Unknown status NCT01473615
26 An Internet-delivered Rumination Focus Cognitive Behavior Therapy in Romania Unknown status NCT03507114
27 An 8-week Open-Label Flexible-Dose Study Of Desvenlafaxine as Monotherapy In The Treatment Of Dysthymia Completed NCT01948895 Desvenlafaxine
28 Healthy Hearts, Healthy Minds Completed NCT01892124
29 The Safety and Effectiveness of Yoga as Augmentation in Improving Residual Depressive Symptoms in Unipolar and Bipolar Disorders. Completed NCT00482482
30 Comprehensive Treatment for Depressed Youth: An Outcome Evaluation Study Completed NCT00096642
31 Development and Evaluation of Enhanced Digital Health Coaching Program for Depressive Symptoms to Support Collaborative Depression Treatment in Primary Care: The RESPECT-D-E (Enhanced) Trial Completed NCT01583400
32 This Was a Five-year Seven-site Trial to Study the Cost-effectiveness of a Population Based Disease Management Program for Late Life Depression in Primary Care. Completed NCT01561105
33 Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention Completed NCT01542957
34 The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels Completed NCT01385709
35 Treatment of Obesity in Depressed Individuals: A Randomized Controlled Trial Completed NCT01692574
36 Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence Completed NCT01528748
37 Randomized, Placebo-Controlled Effectiveness Study of Quetiapine XR in Co-Morbid Depressive and Anxiety Disorders Completed NCT00688818 Quetiapine;Placebo
38 Evaluation of the Effectiveness of Rational Emotive Behavioral Therapy (REBT/CBT) as an Intervention Tool in Clinical Social Work Consultation to Primary Care. Completed NCT02112708
39 An Open-Label Pilot Trial of Cognitive Behavioral Therapy in Familial Dysautonomia Completed NCT03013777
40 Duloxetine for the Treatment of Dysthymia Completed NCT00185575 duloxetine
41 Senzoku Intervention of Schema Therapy for Aid and Recovery From Chronic Depression (SISTAR*CD) Recruiting NCT03084744
42 Clinical Effectiveness of Training for Awareness Resilience and Action (TARA) Compared to Standard Treatment for Adolescents and Young Adults With Depression, a Pragmatic Multi-center Randomised Controlled Superiority-trial Recruiting NCT04747340
43 Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics Recruiting NCT04358900

Search NIH Clinical Center for Dysthymic Disorder

Cochrane evidence based reviews: dysthymic disorder

Genetic Tests for Dysthymic Disorder

Anatomical Context for Dysthymic Disorder

MalaCards organs/tissues related to Dysthymic Disorder:

40
Brain, Breast, Spinal Cord, Skin, Thyroid, Ovary, Eye

Publications for Dysthymic Disorder

Articles related to Dysthymic Disorder:

(show top 50) (show all 2783)
# Title Authors PMID Year
1
Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. 54 61
17346943 2007
2
5-HT2A and 5-HT2C receptors and their atypical regulation properties. 54 61
12650852 2003
3
Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. 61 54
10357046 1999
4
Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. 61 54
9347378 1997
5
Moclobemide versus fluoxetine for double depression: a randomized double-blind study. 61 54
9023788 1996
6
Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia. 54 61
7717093 1995
7
5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. 61 54
1903019 1991
8
Core prescription pattern of Chinese herbal medicine for depressive disorders in Taiwan: a nationwide population-based study. 61
33665095 2021
9
Differential psychopathological profile of male intimate partner violence perpetrators depending on Problematic alcohol use. 61
33714033 2021
10
The prevalence of depression in adult onset idiopathic dystonia: Systematic review and metaanalysis. 61
33662441 2021
11
Estimating the risk of suicide associated with mental disorders: A systematic review and meta-regression analysis. 61
33714076 2021
12
Skin autofluorescence of advanced glycation end products and mortality in affective disorders in the lifelines cohort study: A mediation analysis. 61
33601681 2021
13
Cohort profile of the longitudinal Netherlands Study of Depression and Anxiety (NESDA) on etiology, course and consequences of depressive and anxiety disorders. 61
33773360 2021
14
Change Mechanisms in Brief Interpersonal Psychotherapy for Women With Perinatal Depression: Qualitative Study. 61
33745285 2021
15
Prevalence and Childhood Precursors of Opioid Use in the Early Decades of Life. 61
33369615 2021
16
Systematic review and meta-analysis of the prevalence of depressive symptoms, dysthymia and major depressive disorders among homeless people. 61
33622940 2021
17
External validation of a bifactor model of oppositional defiant disorder. 61
30538308 2021
18
Predicting marriage and divorce in obsessive-compulsive disorder. 61
32783604 2021
19
DetectaWeb-Distress Scale: A Global and Multidimensional Web-Based Screener for Emotional Disorder Symptoms in Children and Adolescents. 61
33658965 2021
20
Is the Thoughts and Health programme feasible in the context of Swedish schools? A quasi-experimental controlled trial study protocol. 61
33483440 2021
21
Spatial working memory performance in children and adolescents with major depressive disorder and dysthymic disorder. 61
33017674 2021
22
Changing parenting style between two generations and its impacts on the severity of behavioral and emotional symptoms. 61
33480179 2021
23
The use of biofeedback intervention in the improvement of depression levels: a randomised trial. 61
33427129 2021
24
Creativity and Psychopathology: An Interdisciplinary View. 61
33326984 2021
25
Relationship between affective temperament and major depressive disorder in older adults: A case-control study. 61
33065837 2020
26
The prevalence of problematic internet use among a sample of Egyptian adolescents and its psychiatric comorbidities. 61
33356734 2020
27
Skin autofluorescence of advanced glycation end products and course of affective disorders in the lifelines cohort study, a prospective investigation. 61
32871673 2020
28
Depression from preschool to adolescence - five faces of stability. 61
33242346 2020
29
Psychiatric comorbidity and temperament-character traits of the patients with lichen simplex chronicus: The relation with the symptom severity of the disease. 61
33034929 2020
30
Minding the treatment gap: results of the Singapore Mental Health Study. 61
31317246 2020
31
Simulation study to demonstrate biases created by diagnostic criteria of mental illnesses: major depressive episodes, dysthymia, and manic episodes. 61
33172939 2020
32
Testosterone, mood, behaviour and quality of life. 61
32657051 2020
33
A Meta-Analysis of the Generalization of the Reliability of State/Trait Depression Inventory Scores. 61
33073753 2020
34
DRD4, DRD2, DAT1, and ANKK1 Genes Polymorphisms in Patients with Dual Diagnosis of Polysubstance Addictions. 61
33171585 2020
35
The role of psychiatric symptoms and environmental vulnerability factors in explaining the relationship between child maltreatment and suicidality: A prospective investigation. 61
32871705 2020
36
Youth diet quality and hazard of mood disorder in adolescence and adulthood among an Australian cohort. 61
32871682 2020
37
Assessing risks of violent extremism in depressive disorders: Developing and validating a new measure of Sympathies for Violent Protest and Terrorism. 61
32702996 2020
38
Association between skin autofluorescence of advanced glycation end products and affective disorders in the lifelines cohort study. 61
32734913 2020
39
Network structure of depression symptomology in participants with and without depressive disorder: the population-based Health 2000-2011 study. 61
32047972 2020
40
Military Combat, Posttraumatic Stress Disorder, and the Course of Alcohol Use Disorders in a Cohort of Australian Vietnam War Veterans. 61
32939901 2020
41
Extremism and common mental illness: cross-sectional community survey of White British and Pakistani men and women living in England. 61
30873926 2020
42
Psychiatric co-morbidities and factors associated with psychogenic non-epileptic seizures: a case-control study. 61
32660849 2020
43
Depressive disorders in Brazil: results from the Global Burden of Disease Study 2017. 61
32993670 2020
44
Treatment of double depression: A meta-analysis. 61
32763535 2020
45
Lifetime and Twelve-Month Prevalence, Persistence, and Unmet Treatment Needs of Mood, Anxiety, and Substance Use Disorders in African American and U.S. versus Foreign-Born Caribbean Women. 61
32992680 2020
46
Parent- and child-reported anxiety disorders differentiating major depressive disorder and dysthymic disorder in children and adolescents. 61
32961097 2020
47
Mental and personality disorders in infertile women with polycystic ovary: a case-control study. 61
33402971 2020
48
Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. 61
32828168 2020
49
Effectiveness and moderators of individual cognitive behavioral therapy versus treatment as usual in clinically depressed adolescents: a randomized controlled trial. 61
32908173 2020
50
The Effects of Exclusively Resistance Training-Based Supervised Programs in People with Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 61
32942633 2020

Variations for Dysthymic Disorder

Expression for Dysthymic Disorder

Search GEO for disease gene expression data for Dysthymic Disorder.

Pathways for Dysthymic Disorder

GO Terms for Dysthymic Disorder

Cellular components related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.8 SLC6A4 HTR2C HTR2A HTR1A HCRT CRH
2 integral component of presynaptic membrane GO:0099056 9.43 SLC6A4 SLC6A3 HTR2A
3 integral component of postsynaptic membrane GO:0099055 9.33 SLC6A4 SLC6A3 HTR2A
4 dendrite GO:0030425 9.1 HTR2C HTR2A HTR1A DRD4 COMT BDNF
5 G protein-coupled serotonin receptor complex GO:0098666 8.96 HTR2C HTR2A

Biological processes related to Dysthymic Disorder according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 POMC INS IL6 HTR2C HTR2A HTR1A
2 G protein-coupled receptor signaling pathway GO:0007186 10.11 POMC INS HTR2C HTR2A HTR1A HCRT
3 positive regulation of gene expression GO:0010628 10.05 SLC6A4 INS IL6 CRP CRH
4 glucose homeostasis GO:0042593 9.84 POMC INS IL6 CRY2
5 memory GO:0007613 9.82 SLC6A4 HTR2A BDNF
6 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.8 HTR2C HTR2A HCRT
7 neurotransmitter transport GO:0006836 9.77 SLC6A4 SLC6A3 SLC6A2
8 acute-phase response GO:0006953 9.75 INS IL6 CRP
9 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.71 HTR2C HTR2A HTR1A DRD4
10 behavioral fear response GO:0001662 9.7 HTR2C HTR1A DRD4
11 synaptic transmission, dopaminergic GO:0001963 9.66 DRD4 CRH
12 neurotransmitter catabolic process GO:0042135 9.65 MAOA COMT
13 sleep GO:0030431 9.65 HTR2A HCRT
14 response to pain GO:0048265 9.65 SLC6A2 CRH COMT
15 negative regulation of potassium ion transport GO:0043267 9.64 HTR2A HCRT
16 negative regulation of lipid storage GO:0010888 9.63 IL6 CRP
17 neurotransmitter reuptake GO:0098810 9.63 SLC6A4 SLC6A2
18 vasoconstriction GO:0042310 9.63 SLC6A4 HTR1A CRP
19 regulation of appetite GO:0032098 9.62 POMC HTR2C
20 serotonin receptor signaling pathway GO:0007210 9.61 HTR2A HTR1A
21 norepinephrine uptake GO:0051620 9.61 SLC6A3 SLC6A2
22 behavior GO:0007610 9.61 HTR2C HTR2A HTR1A
23 dopamine uptake involved in synaptic transmission GO:0051583 9.58 SLC6A3 SLC6A2
24 norepinephrine transport GO:0015874 9.57 SLC6A3 SLC6A2
25 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.56 HTR2C HTR2A
26 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.55 HTR2C HTR2A
27 dopamine catabolic process GO:0042420 9.54 SLC6A3 MAOA COMT
28 regulation of dopamine metabolic process GO:0042053 9.5 SLC6A3 HTR1A DRD4
29 response to drug GO:0042493 9.5 SLC6A4 SLC6A3 SLC6A2 HTR2C HTR2A CRH
30 regulation of serotonin secretion GO:0014062 9.49 HTR1A CRH
31 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.46 HTR2C HTR2A HTR1A DRD4
32 monoamine transport GO:0015844 9.43 SLC6A4 SLC6A3 SLC6A2
33 chemical synaptic transmission GO:0007268 9.17 SLC6A2 HTR2C HTR2A HTR1A HCRT DRD4

Molecular functions related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.62 HTR2C HTR2A HTR1A DRD4
2 dopamine binding GO:0035240 9.48 SLC6A3 DRD4
3 dopamine:sodium symporter activity GO:0005330 9.46 SLC6A3 SLC6A2
4 norepinephrine:sodium symporter activity GO:0005334 9.43 SLC6A3 SLC6A2
5 neurotransmitter transporter activity GO:0005326 9.43 SLC6A4 SLC6A3 SLC6A2
6 Gq/11-coupled serotonin receptor activity GO:0001587 9.4 HTR2C HTR2A
7 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.37 HTR2C HTR2A
8 monoamine transmembrane transporter activity GO:0008504 9.33 SLC6A4 SLC6A3 SLC6A2
9 G protein-coupled serotonin receptor activity GO:0004993 9.26 HTR2C HTR2A HTR1A DRD4
10 serotonin binding GO:0051378 8.92 SLC6A4 HTR2C HTR2A HTR1A

Sources for Dysthymic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....